Cancer Survivors: Late Effects of Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".
Deadline for manuscript submissions: 20 March 2026 | Viewed by 75
Special Issue Editor
Interests: health promotion among diverse communities; cancer care; behavior change research
Special Issue Information
Dear Colleagues,
Cancer survivors are increasingly encountering a range of late effects that can emerge months to years after completing primary therapy. These delayed toxicities, encompassing heart and lung damage, secondary malignancies, endocrine disorders, cognitive decline, chronic fatigue, and emotional distress, can emerge months or even decades after treatment. Historically, survivorship care has focused on acute side effects and recurrence surveillance, often leaving these long-term sequelae unrecognized and unaddressed, thereby exposing patients to preventable morbidity. Therefore, emphasizing late effects is crucial to bridging gaps in care: early identification, risk-stratified monitoring, and evidence-based interventions can mitigate lasting harm, enhance quality of life, and ensure optimal survivorship.
As our knowledge of cancer survivorship deepens, it is essential to bridge research and practice by developing evidence-based interventions that seamlessly integrate into clinical routines. Empowering survivors with these tools not only aids in extending life but also enhances its quality and satisfaction. This Special Issue will feature original research articles and comprehensive reviews that deepen our understanding of the late and post-treatment impacts of cancer therapy.
Dr. Gaurav Kumar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- late effects
- cancer survivorship
- treatment toxicity
- long-term outcomes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
